Manufacturer of Controlled Substances; Notice of Registration: Noramco, Inc., 17231-17232 [2013-06324]

Download as PDF 17231 Federal Register / Vol. 78, No. 54 / Wednesday, March 20, 2013 / Notices material are not appropriate. 72 FR 3417 (2007). DEA has considered the factors in 21 U.S.C. 823(a) and 952(a), and determined that the registration of Noramco Inc., to import the basic classes of controlled substances is consistent with the public interest, and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Noramco, Inc., to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed. Dated: March 12, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–06321 Filed 3–19–13; 8:45 am] BILLING CODE 4410–09–P FDA approved or non-approved dosage form for commercial distribution in the United States. One comment objecting to the granting of registration as an importer of the basic class of controlled substance listed to this applicant and a request for a hearing were received on December 31, 2012. The objection and request for a hearing were withdrawn. DEA has considered the factors in 21 U.S.C. 823(a) and § 952(a) and determined that the registration of Watson Pharma, Inc., to import the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. DEA has investigated Watson Pharma, Inc., to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems; verification of the company’s compliance with state and local laws; and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed. Dated: March 12, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances, Notice of Registration, Watson Pharma, Inc. [FR Doc. 2013–06328 Filed 3–19–13; 8:45 am] By Notice dated November 5, 2012, and published in the Federal Register on November 13, 2012, 77 FR 67675, Watson Pharma, Inc., 2455 Wardlow Road, Corona, California 92880–2882, made application to the Drug Enforcement Administration (DEA) to be registered as an importer of the following basic classes of controlled substances: DEPARTMENT OF JUSTICE Drug Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application: Morton Grove Pharmaceuticals Schedule Amphetamine (1100) .................... Methylphenidate (1724) ................ Oxycodone (9143) ........................ Hydromorphone (9150) ................ srobinson on DSK4SPTVN1PROD with NOTICES BILLING CODE 4410–09–P II II II II The company plans to import the listed controlled substances for analytical testing and clinical trials. The import of the above listed basic classes of controlled substances will be granted only for analytical testing and clinical trials. This authorization does not extend to the import of a finished VerDate Mar<14>2013 18:04 Mar 19, 2013 Jkt 229001 Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on December 14, 2012, Morton Grove Pharmaceuticals, 6451 Main Street, Morton Grove, Illinois 60053–2633, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Gamma Hydroxybutyric Acid (2010), a basic class of controlled substance listed in schedule I. The company plans to manufacture the listed controlled substance for distribution to its customers. Any other such applicant, and any person who is presently registered with DEA to manufacture such substance, PO 00000 Frm 00051 Fmt 4703 Sfmt 4703 may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than May 20, 2013. Dated: March 12, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–06332 Filed 3–19–13; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration: Noramco, Inc. By Notice dated November 1, 2012, and published in the Federal Register on November 9, 2012, 77 FR 67397, Noramco, Inc., 1440 Olympic Drive, Athens, Georgia 30601, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances: Drug Gamma Hydroxybutyric Acid (2010). Codeine-N-Oxide (9053) .............. Dihydromorphine (9145) ............... Morphine-N-oxide (9307) ............. Amphetamine (1100) .................... Methylphenidate (1724) ................ Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Hydrocodone (9193) ..................... Morphine (9300) ........................... Oripavine (9330) ........................... Thebaine (9333) ........................... Oxymorphone (9652) ................... Noroxymorphone (9668) .............. Alfentanil (9737) ........................... Sufentanil (9740) .......................... Carfentanil (9743) ......................... Tapentadol (9780) ........................ Fentanyl (9801) ............................ Schedule I I I I II II II II II II II II II II II II II II II II II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Noramco, Inc., to manufacture the listed E:\FR\FM\20MRN1.SGM 20MRN1 17232 Federal Register / Vol. 78, No. 54 / Wednesday, March 20, 2013 / Notices basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Noramco, Inc., to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: March 12, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–06324 Filed 3–19–13; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Office of Justice Programs [OJP (OVC) Docket No. 1619] Meeting of the SANE/SART AI/AN Initiative Committee Office for Victims of Crime, Justice. ACTION: Notice of meeting. srobinson on DSK4SPTVN1PROD with NOTICES AGENCY: SUMMARY: The National Coordination Committee on the American Indian/ Alaska Native (AI/AN) Sexual Assault Nurse Examiner (SANE)—Sexual Assault Response Team (SART) Initiative (‘‘’’National Coordination Committee’’ or ‘‘Committee’’) will meet to carry out its mission to provide valuable advice to assist the Office for Victims of Crime (OVC) to promote culturally relevant, victim-centered responses to sexual violence within AI/ AN communities. DATES AND LOCATIONS: The meeting will be held via webinar on Wednesday, April 17, 2013. The Webinar is open to the public for participation. There will not be a designated time for the public to speak, however the public can observe and submit comments to Kathleen Gless, the Designated Federal Official. Webinar space is limited. To register for the webinar, please provide your full contact information to Kathleen Gless (contact information below). FOR FURTHER INFORMATION CONTACT: Kathleen Gless, Designated Federal Officer (DFO) for the National VerDate Mar<14>2013 18:04 Mar 19, 2013 Jkt 229001 Coordination Committee, Office for Victims of Crime, Office of Justice Programs, 810 7th Street NW., Washington, DC 20531; Phone: (202) 307–6049 [note: this is not a toll-free number]; Email: kathleen.gless@usdoj.gov. SUPPLEMENTARY INFORMATION: The National Coordination Committee on the American Indian/Alaskan Native (AI/AN) Sexual Assault Nurse Examiner (SANE)—Sexual Assault Response Team (SART) Initiative (‘‘National Coordination Committee’’ or ‘‘Committee’’) was established by the Attorney General to provide valuable advice to OVC to encourage the coordination of federal, tribal, state, and local efforts to assist victims of sexual violence within AI/AN communities, and to promote culturally relevant, victim-centered responses to sexual violence within those communities. Webinar Agenda: The agenda will include: (a) Traditional welcome and introductions; (b) remarks from the Acting Director of OVC; (c) updates on OVC, FBI and IHS efforts since the December 2012 Committee meeting; (d) large group discussion; (e) the development of recommendations regarding the coordination of federal, tribal and local partners to address sexual violence; and (f) a traditional closing. Kathleen Gless, Victim Justice Program Specialist, AI/AN SANE–SART Lead, Designated Federal Official—National Coordination Committee, Office for Victims of Crime. [FR Doc. 2013–06383 Filed 3–19–13; 8:45 am] BILLING CODE 4410–18–P DEPARTMENT OF JUSTICE Office of Justice Programs [OJP (BJA) Docket No. 1616] Meeting of the Global Justice Information Sharing Initiative Federal Advisory Committee Office of Justice Programs (OJP), Justice. ACTION: Notice of meeting. AGENCY: SUMMARY: This is an announcement of a meeting of the Global Justice Information Sharing Initiative (Global) Federal Advisory Committee (GAC) to discuss the Global Initiative, as described at www.it.ojp.gov/global. DATES: The meeting will take place on Thursday, April 11, 2013, from 8:30 a.m. to 4:00 p.m. ET. ADDRESSES: The meeting will take place at the Hilton Crystal City at Washington PO 00000 Frm 00052 Fmt 4703 Sfmt 9990 Reagan National Airport, 2399 Jefferson Davis Highway, Arlington VA 22202, Phone: (703) 418–6800. J. Patrick McCreary, Global Designated Federal Employee (DFE), Bureau of Justice Assistance, Office of Justice Programs, 810 7th Street, Washington, DC 20531; Phone: (202) 616–0532 [note: this is not a toll-free number]; Email: James.P.McCreary@usdoj.gov. FOR FURTHER INFORMATION CONTACT: This meeting is open to the public. Due to security measures, however, members of the public who wish to attend this meeting must register with Mr. J. Patrick McCreary at the above address at least (7) days in advance of the meeting. Registrations will be accepted on a space available basis. Access to the meeting will not be allowed without registration. All attendees will be required to sign in at the meeting registration desk. Please bring photo identification and allow extra time prior to the meeting. Anyone requiring special accommodations should notify Mr. McCreary at least seven (7) days in advance of the meeting. SUPPLEMENTARY INFORMATION: Purpose The GAC will act as the focal point for justice information systems integration activities in order to facilitate the coordination of technical, funding, and legislative strategies in support of the Administration’s justice priorities. The GAC will guide and monitor the development of the Global information sharing concept. It will advise the Assistant Attorney General, OJP; the Attorney General; the President (through the Attorney General); and local, state, tribal, and federal policymakers in the executive, legislative, and judicial branches. The GAC will also advocate for strategies for accomplishing a Global information sharing capability. Interested persons whose registrations have been accepted may be permitted to participate in the discussions at the discretion of the meeting chairman and with approval of the DFE. J. Patrick McCreary, Global Designated Federal Employee, Bureau of Justice Assistance, Office of Justice Programs. [FR Doc. 2013–06359 Filed 3–19–13; 8:45 am] BILLING CODE 4410–18–P E:\FR\FM\20MRN1.SGM 20MRN1

Agencies

[Federal Register Volume 78, Number 54 (Wednesday, March 20, 2013)]
[Notices]
[Pages 17231-17232]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-06324]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration: 
Noramco, Inc.

    By Notice dated November 1, 2012, and published in the Federal 
Register on November 9, 2012, 77 FR 67397, Noramco, Inc., 1440 Olympic 
Drive, Athens, Georgia 30601, made application by renewal to the Drug 
Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of the basic classes of controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid (2010)...........  I
Codeine-N-Oxide (9053).....................  I
Dihydromorphine (9145).....................  I
Morphine-N-oxide (9307)....................  I
Amphetamine (1100).........................  II
Methylphenidate (1724).....................  II
Codeine (9050).............................  II
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Hydrocodone (9193).........................  II
Morphine (9300)............................  II
Oripavine (9330)...........................  II
Thebaine (9333)............................  II
Oxymorphone (9652).........................  II
Noroxymorphone (9668)......................  II
Alfentanil (9737)..........................  II
Sufentanil (9740)..........................  II
Carfentanil (9743).........................  II
Tapentadol (9780)..........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for distribution to its customers.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Noramco, Inc., to manufacture the listed

[[Page 17232]]

basic classes of controlled substances is consistent with the public 
interest at this time. DEA has investigated Noramco, Inc., to ensure 
that the company's registration is consistent with the public interest. 
The investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance 
with 21 CFR 1301.33, the above named company is granted registration as 
a bulk manufacturer of the basic classes of controlled substances 
listed.

    Dated: March 12, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2013-06324 Filed 3-19-13; 8:45 am]
BILLING CODE 4410-09-P